ARTICLE | Financial News
Jounce raises $56M in series B round
April 24, 2015 1:50 AM UTC
Cancer company Jounce Therapeutics Inc. (Cambridge, Mass.) raised $56 million in a series B round from Wellington Management, Redmile Group, Nextech Invest, Pharmstandard International, Cormorant Asset Management, Omega Funds, Casdin Capital, Foresite Capital and an undisclosed public investment fund.
Jounce plans to start clinical testing next year of its inducible T cell co-stimulator (ICOS) agonist antibody. ...